NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS

Abstract

The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Claims

1. (canceled)

2. A protein comprising (i) a fragment of at least seven consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920, or (ii) an amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

3. The protein of claim 2 comprising the fragment, wherein the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

4. The protein of claim 3, wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

5. The protein of claim 3, wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

6. The protein of claim 2 comprising the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

7. The protein of claim 6, wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

8. A composition comprising the protein of claim 2 and a pharmaceutically acceptable excipient.

9. The composition of claim 8, further comprising an adjuvant.

10. The composition of claim 9, wherein the adjuvant is an aluminum salt adjuvant.

11. The composition of claim 10, wherein the aluminum salt adjuvant comprises aluminum hydroxide.

12. The composition of claim 9, wherein the protein comprises the fragment and the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

13. The composition of claim 12, wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

14. The composition of claim 12, wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

15. The composition of claim 9, wherein the protein comprises the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

16. The composition of claim 15, wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920.

17. A method of inducing an immune response in a subject comprising administering the composition of claim 9 to the subject.

Images